Nasdaq: Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
PRINCETON, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the introduction of Simcyp™ Biopharmaceutics software. It is designed ...
Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development
The positions in the table below reflect the Biocity Biopharmaceutics's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to ...
ascopubs.org: Safety, pharmacokinetics, pharmacodynamics profiles and preliminary antitumor activity of phase 1b/2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab in ...
Safety, pharmacokinetics, pharmacodynamics profiles and preliminary antitumor activity of phase 1b/2a study of NT-I7, a long-acting interleukin-7, plus pembrolizumab in ...
TCTMD: TCT 26: Pharmacokinetic Profile of Everolimus Eluted From the Esprit BTK Scaffold: Data From the LIFE-BTK Pharmacokinetics Sub-Study
TCT 26: Pharmacokinetic Profile of Everolimus Eluted From the Esprit BTK Scaffold: Data From the LIFE-BTK Pharmacokinetics Sub-Study
The Phase 1 monotherapy dose escalation portion of MYCHELANGELO I was designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of OTX-2002 ...
Yahoo Finance: Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in ...
Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in ...
Nasdaq: Exelixis to Present the Preclinical Profile and Initial Clinical Pharmacokinetics of XL092, Its Next-Generation Oral Tyrosine Kinase Inhibitor